LOS ANGELES, May 6, 2016 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that the Company has received approval from regulatory
authorities in Canada, the
United Kingdom and the Netherlands to initiate the ICT-107 Phase
3 registration trial in patients with newly diagnosed glioblastoma.
Patient screening is anticipated to commence shortly and the first
clinical supplies could be manufactured for qualifying patients in
Canada and Europe in the third quarter of 2016. The
Company also is near to completing interactions with regulatory
authorities in six other European countries and currently expects
approval of those clinical trial applications in June 2016, with patient screening to begin in the
third quarter of 2016.
"We are very pleased with the progress of our ICT-107
registrational trial in the US, Canada and Europe," said Andrew
Gengos, ImmunoCellular Chief Executive Officer. "We recently
held our European investigator kick off meeting in Barcelona and had 100% attendance of
investigators and coordinators from the 48 European clinical sites
planning to participate in the trial. We are deeply appreciative of
the support and enthusiasm expressed by our European colleagues,
and their recognition of the importance and potential promise of
the ICT-107 program, in light of the high unmet need and lack of
new treatments for patients with brain cancer. We think that the
ICT-107 program could be the best designed registrational program
underway in newly diagnosed glioblastoma and look forward to
announcing the treatment of our first
patient."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. The phase 3 registrational trial of lead product
candidate, ICT-107, a patient-specific, dendritic cell-based
immunotherapy targeting multiple tumor-associated antigens on
glioblastoma stem cells, is open for patient screening.
ImmunoCellular's pipeline also includes: ICT-121, a
patient-specific, dendritic cell-based immunotherapy targeting the
CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a
patient-specific, dendritic cell-based immunotherapy targeting
antigens on ovarian cancer stem cells; and the Stem-to-T-cell
research program which engineers the patient's hematopoietic stem
cells to generate antigen-specific cancer-killing T cells. To learn
more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements,
including statements regarding the development and
commercialization of ICT-107, progress of a Phase 3 study of
ICT-107, including patient screening and enrollment, and our
ability to achieve our other clinical, operational and financial
goals. In some cases, you can identify these statements by
forward-looking words such as "believe," "may," "will,"
"anticipate," "could," "would," "plan," "expect" or the negative or
plural of these words or similar expressions. These statements are
based on ImmunoCellular's current expectations and involve
significant risks and uncertainties, including those described
under the heading "Risk Factors" in ImmunoCellular's most recently
filed quarterly report on Form 10-Q and annual report on Form 10-K.
Except as required by law, ImmunoCellular undertakes no obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-receives-regulatory-approval-in-canada-the-uk-and-the-netherlands-to-initiate-ict-107-phase-3-trial-in-newly-diagnosed-glioblastoma-300264216.html
SOURCE ImmunoCellular Therapeutics, Ltd.